Format

Send to

Choose Destination
J Travel Med. 2020 Mar 18. pii: taaa041. doi: 10.1093/jtm/taaa041. [Epub ahead of print]

Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.

Author information

1
Professor and Head, Environmental and Occupational Health Sciences, School of Public Health; Professor of Anesthesiology, School of Medicine, Louisiana State University Health Sciences Center (LSUHSC), New Orleans, Louisiana, USA.

Abstract

Intravenous infusions of angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) in experimental animals increase the numbers of angiotensin-converting enzyme 2 (ACE2) receptors in the cardiopulmonary circulation. ACE2 receptors serve as binding sites for SARS-CoV-2 virions in the lungs. Patients who take ACEIs and ARBS may be at increased risk of severe disease outcomes due to SARS-CoV-2 infections.

PMID:
32186711
DOI:
10.1093/jtm/taaa041

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center